



Spring Group Meeting

# San Francisco Specials

APRIL 30 - MAY 2, 2026



Melanoma Committee

# Melanoma Committee

## Leadership

Chair: ..... Sapna P. Patel, MD  
 Vice-Chair: ..... Roger S. Lo, MD, PhD  
 Executive Officer:..... Hagen Kennecke, MD, MHA  
 Statisticians: ..... Michael Wu, PhD  
 ..... Megan Othus, PhD  
 ..... James Moon, MS  
 ..... Gabby Lopez, MS  
 ..... Matt Chansky, BS

## Scientific Leadership

Translational Medicine: ..... TBD  
 Radiation Oncology: ..... TBD  
 Surgery: ..... John Robert Hyngstrom, MD  
 Dermatology: ..... TBD  
 Imaging: ..... TBD  
 Medical Oncology: ..... TBD  
 Pathology: ..... TBD  
 Non-Melanoma Skin Cancer: ..... Nikhil I. Khushalani, MD  
 Early Therapeutics: ..... TBD  
 SWOG's ECOG Liaisons: ..... Sunandana Chandra, MD  
 ..... Gerald Paul Wright, Jr., MD  
 ECOG's SWOG Liaisons: ..... David H. Lawson, MD  
 ..... Michael Lowe, MD

## Designates

Prevention: ..... Sancy Leachman, MD, PhD  
 Data Coordinator: ..... Michele Counts, BS  
 ..... Tonya Johnson, BS  
 Oncology Research Professionals: ..... Kathryn Allen, BA, CCRP  
 Patient Advocate: ..... Sara Selig  
 Pharmaceutical Science: ..... Sun "Coco" Yang, PharmD, PhD  
 ..... Stephanie Elise Trexler, PharmD  
 Protocol Project Manager: ..... Catrina De Los Santos-Mireles  
 Clinical Trials Program Manager: ..... Laura Gildner, MS

## Time/Location

Saturday, May 2, 2026 11:30 a.m. - 1:30 p.m.  
 Room: Grand Ballroom B (Street Level)

## Agenda

Welcome & Introductions - Sapna Patel, MD

Keynote Speaker: "Meet our New Patient Advocate: Sara Selig"  
 Sara Selig, MD, MPH

## Active Studies

**A091903**, "A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma."  
 SWOG Champion: K. Tsai, MD (SWOG) Activated 06/01/2022. Temporarily Closed to Accrual as of 10/10/2023. Registration to Arm 3 is Temporarily Closed to Accrual as of 06/16/2025.

## Developing Studies

**S2601**, "Multicenter Selective Lymphadenectomy Trial – III: A randomized phase 3 noninferiority trial of selective lymphadenectomy of index lymph nodes vs. full therapeutic lymphadenectomy in patients with stage III melanoma achieving major pathologic response to neoadjuvant immunotherapy". Dr. Faries

## Closed Studies

**CTSU/EA6141**, "Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma." SWOG Champion: Dr. K. Kim. Activated: 09/10/2015. Closed to accrual as of 1/8/2026.

**S2015**, "Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma." Dr. Mammen. Activated: 04/08/22. Closed to accrual as of 8/28/2025.

**CTSU/EA6192**, "The BAMB2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma with Elevated LDH". SWOG Champion: Dr. Truong. Activated:10/23/2020. Closed to accrual as of 9/3/2025.

**CTSU/EA6174**, "STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial." SWOG Champion: Dr. Hsu. Activated: 10/01/2018. Closed to Accrual as of 07/01/2024.

**S2000**, "A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases." Dr. Eroglu. Activated: 09/23/2020. Closed: 6/18/2024

**S1801**, "A Phase II Randomized Study of Adjuvant Versus Neoadjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High Risk Melanoma." Dr. Patel. Activated: 12/06/18. Closed: 05/05/2022.

**S1512**, "A Phase II and Pilot Trial of PD-1 Blockade with MK-3475

# Melanoma Committee

(Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)." Drs. Kendra and Hu-Lieskovan. Activated: 10/20/16. Closed: 06/04/2021.

**S1607**, "A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy." Dr. Hu-Lieskovan. Activated: 10/02/17. Closed: 11/1/20.

**S1616**, "A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent." Dr. VanderWalde. Activated: 07/17/2017. Closed: 07/15/2020.

**S1404**, "A Phase III Randomized Study of MK3475 versus High-Dose Interferon a-2b for Resected High-Risk Melanoma." Dr. Patel. Activated: 10/15/2015. Closed: 11/02/2017.

**CTS/EA6134**, "DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial." SWOG Champion: Dr. Chmielowski. Activated: 7/13/15. Closed: 9/30/2021.

**CTS/EA6183**, "A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D)." SWOG Champion: C. D. Lao, MD, MPh Activated: 02/18/2020. Closed: 09/23/2022.

## Publications

The publication papers listed below from 2025 and 2026 have not appeared in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

### Published/Accepted Manuscripts

**S1512** Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. K Kendra, S Bellasea, Z Eroglu, S Hu-Lieskovan, K Campbell, W Carson, D Wada, J Plaza, J Sosman, G In, A Ikeguchi, J Hyingstrom, A Brohl, N Khushalani, J Markowitz, G Negrea, S Kasbari, G Doolittle, U Swami, T Roberts, E Medina, I Baselga Carretero, C Gonzalez, I Perez Garcilazo, A Vega-Crespo, J Ming Chen, N Naser Al Deen, S Patel, E Sharon, J Moon, M Wu, A Ribas. *Nature Medicine*. 2025 Nov;31(11):3668-3674. doi: 10.1038/s41591-025-03875-5. Epub 2025 Aug 14. <https://pubmed.ncbi.nlm.nih.gov/40813711/>

**S1512** Neoadjuvant PD-1 blockade in patients with surgically resectable desmoplastic 3 melanoma (SWOG S1512 cohort A). K Kendra, S Bellasea,

Z Eroglu, S Hu-Lieskovan, K Campbell, W Carson, D Wada, J Plaza, G In, A Ikeguchi, J Hyingstrom, A Brohl, B Chmielowski, N Khushalani, J Markowitz, M Monroe, C Contreras, E Medina, C Gonzalez, I Baselga Carretero, I Perez Garcilazo, A Vega-Crespo, J Ming Chen, N Naser Al Deen, S Patel, K Grossmann, V Sondak, E Sharon, J Moon, M Wu, A Ribas. *Nature Cancer*. 2026 Feb;7(2):272-282. doi: 10.1038/s43018-025-01113-y. Epub 2026 Jan 29. <https://pubmed.ncbi.nlm.nih.gov/41611998/>

**S1616** Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1. Katie M. Campbell, Daniel G. Chen, Zaid E. Bustami, Nataly Naser Al Deen, Egmidio Medina, Cynthia R. Gonzalez, Jessica Maxey, Marshall A. Thompson, Sarah Samorodnitsky, Lawrence F. Kuklinski, Ivan Perez Garcilazo, Ignacio Baselga-Carretero, Agustin Vega-Crespo, Jia Ming Chen, Rangasamy Elumalai, Marc Visitacion, Rob Schiemann, Lacey Padron, Cadence Chang, Alan E. Zelin, Sai S. Chelluri, Silvia Boffo, Kari L. Kendra, Bartosz Chmielowski, Thach-Giao Truong, Nikhil I. Khushalani, Frances Collichio, Alexandra Ikeguchi, Adrienne I. Victor, Kim Margolin, Douglas B. Johnson, Yuanbin Chen, Jeffrey A. Sosman, Sapna P. Patel, Siwen Hu-Lieskovan, James Moon, Daniel K. Wells, Christine N. Spencer, Shay Bellasea, Ari M. Vanderwalde, Michael Wu, Philip O. Scumpia, Antoni Ribas. Accepted 2026.

**E1609** Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma. Ahmad A Tarhini, Alyssa Obermayer, Sandra J Lee, William A LaFramboise, F Stephen Hodi, Arivarasan D Karunamurthy, Islam Eljilany, Dung-Tsa Chen, Patrick Hwu, Issam M El Naqa, Howard Streicher, Vernon K Sondak, Walter J Storkus, Lisa H Butterfield, Timothy I Shaw, John M Kirkwood. *Clin Cancer Res*. 2025 Aug 1;31(15):3249-3258. doi: 10.1158/1078-0432.CCR-24-3980. NIHMS2085262. <https://pubmed.ncbi.nlm.nih.gov/40392969>

**E1609** Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors. Xuefeng Wang, Tingyi Li, Islam Eljilany, Alex Soupir, Michael Radmacher, Phaedra Agius, Vineeth Sukrithan, Aakrosh Ratan, Martin McCarter, Bodour Salhia, Howard Colman, Abdul R Naqash, Igor Puzanov, Susanne Arnold, Julian A Marin-Acevedo, Shridar Ganesan, Michelle Churchman, Patrick Hwu, Paulo C Rodriguez, William S Dalton, George J Weiner, Ahmad A Tarhini. *Nat Commun*. 2025 Nov 13;16(1):9968. doi: 10.1038/s41467-025-65016-3 <https://pubmed.ncbi.nlm.nih.gov/41233329/>

### Submitted Manuscripts

None this cycle

## Melanoma Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S2015	A091903	EA6141	EA6192	EA6194
Banner MD Anderson Cancer Center	39	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	1	1
Cancer Research Consortium of West Michigan NCORP	112	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	1	-	-
Cedars-Sinai Medical Center	30	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	3	-	-
Columbia University Minority Underserved NCORP	9	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	2	-	-
Duke University - Duke Cancer Institute LAPS	20	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	15	-	-	-	-
Georgia NCI Community Oncology Research Program	11	-	-	-	-
Intermountain Medical Center	44	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	6	-	31	-	-
Medical University of So Carolina Minority Underserved NCORP	20	-	-	-	-
Moffitt Cancer Center	58	-	-	-	-
New Mexico Minority Underserved NCORP	7	-	-	-	-
Northwell Health NCORP	10	-	-	-	-
Northwestern University LAPS	46	-	1	5	-
Ohio State University Comprehensive Cancer Center LAPS	36	-	-	3	-
Regents of the University of Michigan	25	-	1	-	-
Sutter Cancer Research Consortium	-	-	7	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	18	-	4	-	3
USC Norris Comprehensive Cancer Center LAPS	5	1	-	-	-
University of Arkansas for Medical Sciences	7	-	-	1	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	2	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	48	-	3	-	-
University of Kentucky/Markey Cancer Center	13	-	-	-	-
University of Nebraska Medical Center	4	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	1	-	-	-	-
University of Rochester LAPS	7	-	13	-	-
University of Texas Health Science Center at San Antonio	3	-	1	-	-
University of Texas MD Anderson Cancer Center LAPS	23	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	33	-	-	-	-
Western States Cancer Research NCORP	-	-	1	-	-
Wisconsin NCI Community Oncology Research Program	16	-	-	-	-
Yale University - Yale Cancer Center LAPS	29	-	8	-	-
ALLIANCE	132	-	-	-	-
ECOG-ACRIN	228	-	-	-	-
NRG	102	-	-	-	-
<b>Total</b>	<b>1,157</b>	<b>1</b>	<b>78</b>	<b>10</b>	<b>4</b>

